Randomized trial investigates ethyl gallate's protection against liver injury in rats, suggesting its therapeutic potential.
Acute liver injury (ALI) is characterized by the rapid onset of liver dysfunction, which may progress to acute liver failure within a short period. Thioacetamide (TAA) is widely known to induce hepatotoxicity through mechanisms involving oxidative stress, cell death, inflammation, fibrosis, and cirrhosis. Ethyl gallate (EG), a polyphenolic compound, is recognized for its potent antioxidant and free radical scavenging properties. The present study investigated the hepatoprotective role of EG on TAA-induced ALI through the Nrf2/MAPK/NF-κB associated signaling pathways in rats. Female Wistar rats were divided into six groups (n = 6) as control, TAA (350 mg/kg, i.p.,), TAA + EG (10 & 20 mg/kg, p.o.,), TAA + silymarin (SIL) (100 mg/kg, p.o.,) and EG (20 mg/kg, p.o.,). TAA, EG, and SIL were administered as a single dose, and animals were euthanized 24 h after treatment. TAA administration caused a significant elevation in serum liver marker enzymes, as well as oxidative stress and inflammatory markers in liver tissue, indicating the onset of ALI. Co-treatment with EG and SIL significantly reduced elevated liver enzymes and oxidative stress markers, while restoring hepatic antioxidant status. Both treatments downregulated MAPK signaling pathway and NF-κB signaling pathway, and upregulated Nrf2 signaling pathway markers. Notably, high-dose EG (20 mg/kg) markedly prevented hepatocellular damage in TAA-induced rats. Overall, the findings of this study demonstrate the hepatoprotective potential of EG against TAA-induced acute liver injury through modulation of Nrf2 (sMaf, NQO1, Keap1, and Cul3), MAPK (JNK1, c-Jun, ERK1, ASK1, p38, and Bcl2), and NF-κB signaling pathways in rats.
No takes yet. Share an insight, caveat, or question.
Karthick et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: